Cargando…

Pseudomonas aeruginosa in Cancer Therapy: Current Knowledge, Challenges and Future Perspectives

Drug resistance, undesirable toxicity and lack of selectivity are the major challenges of conventional cancer therapies, which cause poor clinical outcomes and high mortality in many cancer patients. Development of alternative cancer therapeutics are highly required for the patients who are resistan...

Descripción completa

Detalles Bibliográficos
Autores principales: Pang, Zheng, Gu, Meng-Di, Tang, Tong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9095937/
https://www.ncbi.nlm.nih.gov/pubmed/35574361
http://dx.doi.org/10.3389/fonc.2022.891187
_version_ 1784705862976143360
author Pang, Zheng
Gu, Meng-Di
Tang, Tong
author_facet Pang, Zheng
Gu, Meng-Di
Tang, Tong
author_sort Pang, Zheng
collection PubMed
description Drug resistance, undesirable toxicity and lack of selectivity are the major challenges of conventional cancer therapies, which cause poor clinical outcomes and high mortality in many cancer patients. Development of alternative cancer therapeutics are highly required for the patients who are resistant to the conventional cancer therapies, including radiotherapy and chemotherapy. The success of a new cancer therapy depends on its high specificity to cancer cells and low toxicity to normal cells. Utilization of bacteria has emerged as a promising strategy for cancer treatment. Attenuated or genetically modified bacteria were used to inhibit tumor growth, modulate host immunity, or deliver anti-tumor agents. The bacteria-derived immunotoxins were capable of destructing tumors with high specificity. These bacteria-based strategies for cancer treatment have shown potent anti-tumor effects both in vivo and in vitro, and some of them have proceeded to clinical trials. Pseudomonas aeruginosa, a Gram-negative bacterial pathogen, is one of the common bacteria used in development of bacteria-based cancer therapy, particularly known for the Pseudomonas exotoxin A-based immunotoxins, which have shown remarkable anti-tumor efficacy and specificity. This review concisely summarizes the current knowledge regarding the utilization of P. aeruginosa in cancer treatment, and discusses the challenges and future perspectives of the P. aeruginosa-based therapeutic strategies.
format Online
Article
Text
id pubmed-9095937
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-90959372022-05-13 Pseudomonas aeruginosa in Cancer Therapy: Current Knowledge, Challenges and Future Perspectives Pang, Zheng Gu, Meng-Di Tang, Tong Front Oncol Oncology Drug resistance, undesirable toxicity and lack of selectivity are the major challenges of conventional cancer therapies, which cause poor clinical outcomes and high mortality in many cancer patients. Development of alternative cancer therapeutics are highly required for the patients who are resistant to the conventional cancer therapies, including radiotherapy and chemotherapy. The success of a new cancer therapy depends on its high specificity to cancer cells and low toxicity to normal cells. Utilization of bacteria has emerged as a promising strategy for cancer treatment. Attenuated or genetically modified bacteria were used to inhibit tumor growth, modulate host immunity, or deliver anti-tumor agents. The bacteria-derived immunotoxins were capable of destructing tumors with high specificity. These bacteria-based strategies for cancer treatment have shown potent anti-tumor effects both in vivo and in vitro, and some of them have proceeded to clinical trials. Pseudomonas aeruginosa, a Gram-negative bacterial pathogen, is one of the common bacteria used in development of bacteria-based cancer therapy, particularly known for the Pseudomonas exotoxin A-based immunotoxins, which have shown remarkable anti-tumor efficacy and specificity. This review concisely summarizes the current knowledge regarding the utilization of P. aeruginosa in cancer treatment, and discusses the challenges and future perspectives of the P. aeruginosa-based therapeutic strategies. Frontiers Media S.A. 2022-04-28 /pmc/articles/PMC9095937/ /pubmed/35574361 http://dx.doi.org/10.3389/fonc.2022.891187 Text en Copyright © 2022 Pang, Gu and Tang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Pang, Zheng
Gu, Meng-Di
Tang, Tong
Pseudomonas aeruginosa in Cancer Therapy: Current Knowledge, Challenges and Future Perspectives
title Pseudomonas aeruginosa in Cancer Therapy: Current Knowledge, Challenges and Future Perspectives
title_full Pseudomonas aeruginosa in Cancer Therapy: Current Knowledge, Challenges and Future Perspectives
title_fullStr Pseudomonas aeruginosa in Cancer Therapy: Current Knowledge, Challenges and Future Perspectives
title_full_unstemmed Pseudomonas aeruginosa in Cancer Therapy: Current Knowledge, Challenges and Future Perspectives
title_short Pseudomonas aeruginosa in Cancer Therapy: Current Knowledge, Challenges and Future Perspectives
title_sort pseudomonas aeruginosa in cancer therapy: current knowledge, challenges and future perspectives
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9095937/
https://www.ncbi.nlm.nih.gov/pubmed/35574361
http://dx.doi.org/10.3389/fonc.2022.891187
work_keys_str_mv AT pangzheng pseudomonasaeruginosaincancertherapycurrentknowledgechallengesandfutureperspectives
AT gumengdi pseudomonasaeruginosaincancertherapycurrentknowledgechallengesandfutureperspectives
AT tangtong pseudomonasaeruginosaincancertherapycurrentknowledgechallengesandfutureperspectives